These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33181406)

  • 1. Cytoplasmic CCR7 (CCR7c) immunoexpression is associated with local tumor recurrence in triple-negative breast cancer.
    Gurgel DC; Wong DVT; Bandeira AM; Pereira JFB; Gomes-Filho JV; Pereira AC; Barros Silva PG; Távora FRF; Pereira AF; Lima-Júnior RCP; Almeida PRC
    Pathol Res Pract; 2020 Dec; 216(12):153265. PubMed ID: 33181406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer.
    Li X; Sun S; Li N; Gao J; Yu J; Zhao J; Li M; Zhao Z
    Cell Physiol Biochem; 2017; 43(2):531-539. PubMed ID: 28930757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer.
    Liu M; Tsang JYS; Lee M; Ni YB; Chan SK; Cheung SY; Hu J; Hu H; Tse GMK
    J Clin Pathol; 2018 Nov; 71(11):1007-1014. PubMed ID: 30099407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Human Epidermal Growth Factor 2 is a Novel Biomarker for Recurrence and Metastasis in Triple Negative Breast Cancer.
    Yang H; Chen L; Zhou L; Liu C; Tang L; Zhang J; Fan F; Zhong Z; Shi G; Li Z
    Clin Lab; 2017 Jan; 63(1):53-58. PubMed ID: 28164487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma.
    Li X; Wei B; Sonmez C; Li Z; Peng L
    Hum Pathol; 2017 Aug; 66():222-229. PubMed ID: 28655638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Lox in triple-negative breast cancer.
    Leo C; Cotic C; Pomp V; Fink D; Varga Z
    Ann Diagn Pathol; 2018 Jun; 34():98-102. PubMed ID: 29661738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
    Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
    Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.